Space Flap for Cerebral Protection Following Decompressive Hemicraniectomy for Stroke

April 26, 2021 updated by: University Hospital Inselspital, Berne

In this study the investigators want to investigate to what extent the application of an artificial bone flape (space flap) influences the success of a decompressive craniectomy.

In all participants, a space flap is placed immediately after removal of the skull cap. In a second operation, after 1-3 months, an operation is performed, in which the stored own skull bone is re-inserted. The artificial bone cover is removed at this point.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The destruction of local brain parenchyma after cerebral infarction leads to local swelling within a few days. In the beginning the ischemic brain expand at the expense of the CSF and venous spaces. However, once these spaces are partially displaced further swelling invariably leads to increase of the intracranial pressure due to the limited space available inside the cranial vault. In cases of large infarctions this increase in intracranial pressure (ICP) may entail life threatening secondary injuries to the brain. The surgical removal of a large part of the skull (decompressive hemi-craniectomy) allows the ischemic brain to expand, therefore avoiding an increase of ICP and it's deleterious effects. After removal of a part of the skull the skin is closed again, and the skull flap is kept in sterile environment. Several months after decompression craniectomy patients undergo implantation of either their preserved bone flap or of a bone flap substitute (so-called patient specific implant, or PSI, mostly made out of Palacos®).

Decompressive hemi-craniectomy comes at a cost for the patient, despite its undisputed role as a life saving surgery after large cerebral infarction. During the first days after surgery the brain may use the space freed up by bone removal. In some cases the brain may prolapse even further out of the cranial vault, leading to brain herniation. Brain herniation are common and may lead to further damage due to axonal shearing injuries in the brain, and to hemorrhages and infarction at the craniotomy edges. The lack of the protective skull prior to re-implantation of the bone flap puts the brain at risk of injuries due to falls during rehabilitation and exposes the brain indirectly to atmospheric pressure. Various neurological deficits subsumed as the syndrome of the trephined have been described in these patients. The symptoms of the syndrome of the trephined have in common that they appear a few weeks after decompression and significantly improve after re-implantation of the patient's own bone. The symptoms range from orthostatic headache and dizziness to motor paresis, aphasia, cognitive decline and brainstem compression symptoms. The pathophysiology behind the syndrome of the trephined can be understood as an "open box" phenomenon. After removal of the bone the brain is separated from the atmospheric pressure only by the skin. The skin, however, does not hold against atmospheric pressure and sinks into the skull cavity (sinking skin flap) once the brain swelling diminishes. Physiologic dynamics of the cerebrospinal fluid are deranged, leading to hydrocephalus, subdural hygromas and parenchymal effusions. This assumption is enforced by pathophysiological observations of decreased cerebral blood flow in both hemispheres following decompression, and normalization thereof following re-implantation of the bone flap.

This pilot study aims at assessing feasibility of a change in surgical protocol. The rate of ICP control will be used to determine the sample size of a planned monocenter study.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bern, Switzerland, 3010
        • Dep. of Neurosurgery, Bern University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age between 18 and 65 years
  • Decompressive hemi-craniectomy planed for*:

    • Impairment of consciousness or progressive reduction of consciousness and
    • Mass effect on brain imaging (oedema exceeding 50% of the MCA territory and midline shift), and
    • Exclusion of other causes of impaired consciousness (e.g. hypoperfusion, hypotension, cerebral reinfarction, epileptic seizures
  • Informed consent from relatives

Exclusion Criteria:

  • Bilateral, nonreactive, not drug-induced pupillary dilation, associated with coma*
  • Simultaneous presence of all four of the following unfavorable prognostic factors: *

    • Age 50 years
    • Involvement of additional vascular territories
    • Unilateral pupillary dilation
    • GCS<8
  • Severe comorbidity (severe heart failure or myocardial infarction, incurable neoplasia, etc. *
  • Refusal by the patient of this treatment, as known from current interaction with the patient, from existing written documents or related by the patient's proxies. *
  • Known pulmonary or cranial infection
  • Any coagulopathy
  • Rapid neurological decline prohibiting the extra time needed for space flab production (10min)
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Space Flap
A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ICP Control
Time Frame: 1 day after surgery
ICP Control (number of hours with mean ICP equal to or > 20mmHg)
1 day after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intracranial infections
Time Frame: 1 day after surgery
Intracranial infections (proven by microbiology)
1 day after surgery
Postoperative hematomas
Time Frame: 1 day after surgery
Postoperative hematomas localized at the edge of the craniotomy
1 day after surgery
Postoperative infarctions
Time Frame: 1 day after surgery
Postoperative infarctions localized at the edge of the craniotomy
1 day after surgery
Brain herniation
Time Frame: 1 day after surgery
Brain herniation (>1.5cm out of cranial vault)
1 day after surgery
Syndrom of the trephined
Time Frame: 1 day after surgery
Syndrom of the trephined assessed by MRI/CT Scan
1 day after surgery
Hydrocephalus malresorptivus
Time Frame: 1 month after surgery
Hydrocephalus malresorptivus assessed by MRI/CT Scan
1 month after surgery
Adhesions between the brain and the skin
Time Frame: 1 month after surgery
Adhesions between the brain and the skin
1 month after surgery
Adhesions between the palacos and the temporal muscle
Time Frame: 1 month after surgery
Adhesions between the palacos and the temporal muscle
1 month after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Schucht Philippe, MD, Dep. of Neurosurgery, Bern University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2012

Primary Completion (Actual)

August 1, 2020

Study Completion (Actual)

September 1, 2020

Study Registration Dates

First Submitted

April 22, 2021

First Submitted That Met QC Criteria

April 26, 2021

First Posted (Actual)

April 29, 2021

Study Record Updates

Last Update Posted (Actual)

April 29, 2021

Last Update Submitted That Met QC Criteria

April 26, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 080/12

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infarction

Clinical Trials on Space Flap

3
Subscribe